A Phase 2 interventional study of G-CSF Plus Plerixafor in Hodgkin's Disease, sponsored by Genzyme, a Sanofi Company. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-03-13.
Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Granulocyte Colony-Stimulating Factor in Hodgkin Disease — 1 open to participants now, 1 under way, none of them phase 3. Granulocyte Colony-Stimulating Factor · Hodgkin Disease.
Among the 12 studies testing Granulocyte Colony-Stimulating Factor in Hodgkin Disease, this one is the 8th largest by enrollment, is one of 2 that started in 2004, is one of 10 in phase 2, and was the 4th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →1 of the 12 studies testing Granulocyte Colony-Stimulating Factor in Hodgkin Disease is open now, in 1 country. Recruiting first, the newest first:
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages up to 75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 28 across the 12 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genzyme, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Genzyme, a Sanofi Company is the lead sponsor of 308 studies on the registry; 5 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 19 (76%) have results posted.
Sanofi has 5 studies filed under Hodgkin Disease — fewer than ten, so there is no comparison to draw.
1 of the studies testing Granulocyte Colony-Stimulating Factor in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03125642Masonic Cancer Center, University of MinnesotaAuto Stem Cell Transplant for Lymphoma Patients | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing Granulocyte Colony-Stimulating Factor in Hodgkin Disease, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Participants with Hodgkin's Disease (HD) who have been treated with cyto-reductive chemotherapy, who are to undergo autologous stem cell transplantation, and who meet the inclusion/exclusion criteria are eligible to enter this efficacy, safety and pharmacokinetic (PK) study. The only changes to the standard of care is the addition of plerixafor to a granulocyte-colony stimulating factor (G-CSF) mobilization regimen on each day prior to apheresis. The purpose of this protocol is to determine the proportion of participants who reach a target number of CD34+ stem cells (≥5*10\^6 cells/kg) after hematopoietic stem cell mobilization with G-CSF and plerixafor. Safety and PK parameters are also collected.
Participants with HD who have been treated with cyto-reductive chemotherapy, who are to undergo autologous stem cell transplantation, and who meet the inclusion/exclusion criteria are eligible to enter this study. The only changes to the standard of care is the addition of plerixafor to a G-CSF mobilization regimen on the day prior to apheresis and the collection of blood samples for pharmacokinetic (PK) analysis and pharmacodynamics (PD) analysis by CD34+ fluorescence-activated cell sorting (FACS) analysis. Blood samples for PK and CD34+ FACS analyses will be obtained prior to and after the first dose of plerixafor. Participants will undergo mobilization with G-CSF (10 µg/kg daily) and will receive plerixafor (240 µg/kg) on each day prior to apheresis. Participants will be apheresed for up to 5 consecutive days in order to collect the target number of CD34+ stem cells, (≥5*10\^6 cells/kg). After apheresis, all participants will be treated with high dose chemotherapy in preparation for transplantation. Participants will be transplanted with cells obtained from the G-CSF plus plerixafor mobilization regimen. In the event that a sufficient number of cells for transplantation are not obtained from the collection, cells may be retained and pooled for transplantation at the investigator's discretion.
The primary endpoint is the proportion of HD participants who collect ≥5*10\^6 CD34+ cells/kg with this mobilization regimen. The secondary endpoints include the safety of this mobilization regimen, the proportion of participants who collect ≥2*10\^6 CD34+ cells/kg, the change in CD34+ cells circulating in the peripheral blood after a dose of plerixafor, and the number of days of apheresis required to obtain ≥5*10\^6 CD34+ cells/kg. In addition, success of the transplantation will be evaluated by measuring the time to engraftment of PMNs and PLTs. Participants will be followed for 12 months to assess transplant durability.
This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with Hodgkin's Disease who were eligible for autologous peripheral blood stem cell transplantation.
Drug: G-CSF Plus Plerixafor
Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor
Randomized participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected.
Also known as: Mozobil, AMD3100
Proportion of Participants Who Achieved ≥5*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF
The proportion of total participants who mobilized ≥5\*10\^6 CD34+ cells/kg based on data from local laboratories.
Time frame: Day 5 up to Day 9
Overall Participant Counts of Adverse Events During the Treatment Period
Adverse Events were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe and life-threatening) and relatedness (5 steps from 'not related' to 'definitely related') to study treatment. Time frame starts on the first day of G-CSF mobilization to the day prior to chemotherapy/ablative treatment in preparation for transplant. See the separate Serious Adverse Event section for a summary of AEs the investigator assessed as serious.
Time frame: Day 0 - approximately day 38
Proportion of Participants Who Achieved ≥2*10^6 CD34+ Cells/kg Following Treatment With Plerixafor and G-CSF
The proportion of total participants who mobilized ≥2\*10\^6 CD34+ cells/kg based on data from local laboratories.
Time frame: Day 5 up to day 9
Fold (Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL
The fold increase was measured by fluorescence activated cell sorting (FACS) analysis using local laboratory data and was expressed as a ratio. Fold increase = (pre-apheresis PB CD34+ cells/µL)/(pre-plerixafor dosing PB CD34+ cells/µL).
Time frame: Days 4-5 (first dose of plerixafor to apheresis)
Participant Counts Grouped by Number of Apheresis Days Required to Collect ≥ 5*10^6 CD34+ Cells/kg
Counts of participants grouped by the number of apheresis days needed to collect a target for transplantation of ≥5\*10\^6 CD34+ cells/kg as determined by local laboratory data.
Time frame: Day 5 up to day 9
Number of Days Post-Transplantation to Polymorphonuclear Leukocyte (PMN) Engraftment
Median number of days to PMN engraftment following transplantation. Engraftment was defined as PMN counts ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.
Time frame: Up to Month 13 (up to 12 months post transplant)
Number of Days Post Transplantation to Platelet (PLT) Engraftment
Median number of days to PLT engraftment following transplantation. Engraftment success was evaluated according to local site practice. Time to engraftment corresponded to the first day that criteria were met.
Time frame: Up to Month 13 (up to 12 months post transplant)
Number of Participants With a Durable Graft at 12 Months
Graft durability was assessed by the Investigator based on complete blood count (CBC) and differential analyses at 12 months post transplantation. A graft was considered durable if blood counts were normal (acceptable) and still met the criteria for PLT and PMN engraftment.
Time frame: 13 months
Maximum Plasma Concentration (Cmax) Following a Single Dose of Plerixafor
Maximum plasma concentration (Cmax) of plerixafor following the first single dose of 240 ug/kg plerixafor administered.
Time frame: Day 4
Time to Maximum Plasma Concentration (Tmax) Following a Single Dose of Plerixafor
Time to maximum plasma concentration (Tmax) of plerixafor following the first single dose of 240 ug/kg plerixafor was determined from direct observation of the data.
Time frame: Day 4
Half-life (T1/2) Following a Single Dose of Plerixafor
Plasma elimination half-life (T1/2) following a single dose of 240 ug/kg plerixafor.
Time frame: Day 4
Area Under the Plasma Concentration-time Curve From 0 to 10 Hours (AUC0-10) Following a Single Dose of Plerixafor
Area under the plasma concentration-time curve from 0 to 10 hours (AUC0-10) following the first single dose of 240 ug/kg plerixafor.
Time frame: Days 4-5
Apparent Clearance (CL/F) of Single-dose Plerixafor
Apparent clearance was calculated the mean dose of plerixafor divided by the area under the plasma concentration-time curve from 0 hours to infinity (AUC0-inf).
Time frame: Day 4-5
Apparent Volume of Distribution (Vz/F) Following a Single-dose of Plerixafor
The volume of distribution (Vz/F) was calculated as apparent clearance divided by the terminal elimination rate constant.
Time frame: Day 4
| Milestone | Participants With Hodgkin's Disease (HD) |
|---|---|
| Started | 22 |
| Completed | 22 |
| Not completed | 0 |
| Milestone | Participants With Hodgkin's Disease (HD) |
|---|---|
| Started | 21 |
| Completed | 21 |
| Not completed | 0 |
The proportion of total participants who mobilized ≥5\*10\^6 CD34+ cells/kg based on data from local laboratories.
| proportion of participants | Participants With Hodgkin's Disease (HD) |
|---|---|
| Proportion achieving ≥5*10^6 CD34+ cells/kg | 0.68 |
| Proportion not achieving ≥5*10^6 CD34+ cells/kg | 0.32 |
Adverse Events were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe and life-threatening) and relatedness (5 steps from 'not related' to 'definitely related') to study treatment. Time frame starts on the first day of G-CSF mobilization to the day prior to chemotherapy/ablative treatment in preparation for transplant. See the separate Serious Adverse Event section for a summary of AEs the investigator assessed as serious.
| participants | Participants With Hodgkin's Disease (HD) |
|---|---|
| Reporting at least one AE | 17 |
| Severity - Mild | 5 |
| Severity - Moderate | 11 |
| Severity - Severe | 1 |
| Severity - Life Threatening | 0 |
| Relationship - Not Related | 2 |
| Relationship - Probably Not Related | 1 |
| Relationship - Possibly Related | 12 |
| Relationship - Probably Related | 1 |
| Relationship - Definitely Related | 1 |
The proportion of total participants who mobilized ≥2\*10\^6 CD34+ cells/kg based on data from local laboratories.
| proportion of participants | Participants With Hodgkin's Disease (HD) |
|---|---|
| Proportion achieving ≥2*10^6 CD34+ cells/kg | 0.95 |
| Proportion not achieving ≥2*10^6 CD34+ cells/kg | 0.05 |
The fold increase was measured by fluorescence activated cell sorting (FACS) analysis using local laboratory data and was expressed as a ratio. Fold increase = (pre-apheresis PB CD34+ cells/µL)/(pre-plerixafor dosing PB CD34+ cells/µL).
| ratio | Participants With Hodgkin's Disease (HD) |
|---|---|
| Fold (Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL | 3.2 ± 1.1 |
Counts of participants grouped by the number of apheresis days needed to collect a target for transplantation of ≥5\*10\^6 CD34+ cells/kg as determined by local laboratory data.
| participants | Participants With Hodgkin's Disease (HD) |
|---|---|
| 1 day of apheresis | 7 ± 0.9 |
| 2 days of apheresis | 6 |
| 3 days of apheresis | 2 |
Median number of days to PMN engraftment following transplantation. Engraftment was defined as PMN counts ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met.
| days | Participants With Hodgkin's Disease (HD) |
|---|---|
| Number of Days Post-Transplantation to Polymorphonuclear Leukocyte (PMN) Engraftment | 9.0 ± 1.2 |
Median number of days to PLT engraftment following transplantation. Engraftment success was evaluated according to local site practice. Time to engraftment corresponded to the first day that criteria were met.
| days | Participants With Hodgkin's Disease (HD) |
|---|---|
| Number of Days Post Transplantation to Platelet (PLT) Engraftment | 19.0 ± 3.8 |
Graft durability was assessed by the Investigator based on complete blood count (CBC) and differential analyses at 12 months post transplantation. A graft was considered durable if blood counts were normal (acceptable) and still met the criteria for PLT and PMN engraftment.
| participants | Participants With Hodgkin's Disease (HD) |
|---|---|
| Number of Participants With a Durable Graft at 12 Months | 21 |
Maximum plasma concentration (Cmax) of plerixafor following the first single dose of 240 ug/kg plerixafor administered.
| ng/mL | Participants With Hodgkin's Disease (HD) |
|---|---|
| Maximum Plasma Concentration (Cmax) Following a Single Dose of Plerixafor | 831 ± 183 |
Time to maximum plasma concentration (Tmax) of plerixafor following the first single dose of 240 ug/kg plerixafor was determined from direct observation of the data.
| hours | Participants With Hodgkin's Disease (HD) |
|---|---|
| Time to Maximum Plasma Concentration (Tmax) Following a Single Dose of Plerixafor | 0.6 ± 0.4 |
Plasma elimination half-life (T1/2) following a single dose of 240 ug/kg plerixafor.
| hours | Participants With Hodgkin's Disease (HD) |
|---|---|
| Half-life (T1/2) Following a Single Dose of Plerixafor | 3.5 ± 0.7 |
Area under the plasma concentration-time curve from 0 to 10 hours (AUC0-10) following the first single dose of 240 ug/kg plerixafor.
| ng*hr/mL | Participants With Hodgkin's Disease (HD) |
|---|---|
| Area Under the Plasma Concentration-time Curve From 0 to 10 Hours (AUC0-10) Following a Single Dose of Plerixafor | 3572 ± 772 |
Apparent clearance was calculated the mean dose of plerixafor divided by the area under the plasma concentration-time curve from 0 hours to infinity (AUC0-inf).
| mL/hr | Participants With Hodgkin's Disease (HD) |
|---|---|
| Apparent Clearance (CL/F) of Single-dose Plerixafor | 5138 ± 2029 |
The volume of distribution (Vz/F) was calculated as apparent clearance divided by the terminal elimination rate constant.
| mL | Participants With Hodgkin's Disease (HD) |
|---|---|
| Apparent Volume of Distribution (Vz/F) Following a Single-dose of Plerixafor | 25464 ± 9002 |
Collected over Day 1 (start of G-CSF Mobilization plus Treatment/Apheresis) to the day before starting chemotherapy. Chemotherapy typically started within 30 days of the last apheresis (which may have occurred on Day 5, 6, 7, or 8).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants With Hodgkin's Disease (HD) | — | 0/22 (0%) | 17/22 (77.3%) |
| Event | Participants With Hodgkin's Disease (HD) |
|---|---|
| Injection site erythemaGeneral disorders | 15/22 |
| Back painMusculoskeletal and connective tissue disorders | 7/22 |
| NauseaGastrointestinal disorders | 6/22 |
| Bone painMusculoskeletal and connective tissue disorders | 6/22 |
| FatigueGeneral disorders | 5/22 |
| ParaesthesiaNervous system disorders | 5/22 |
| Paraesthesia oralGastrointestinal disorders | 4/22 |
| DiarrhoeaGastrointestinal disorders | 3/22 |
| Injection site haemorrhageGeneral disorders | 3/22 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/22 |
| Age, Continuous(years) | Participants With Hodgkin's Disease (HD) |
|---|---|
| Mean | 34.0 ± 12.5 |
| Sex: Female, Male(Participants) | Participants With Hodgkin's Disease (HD) |
|---|---|
| Female | 13 |
| Male | 9 |
| Race/Ethnicity, Customized(participants) | Participants With Hodgkin's Disease (HD) |
|---|---|
| Caucasian | 22 |
The record gives a start of Nov 2004, a primary completion of Oct 2006 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2010, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor